A nonmyeloablative conditioning regimen consisting of fludarabine (FLU) and 2 Gy TBI has been used extensively and with substantial engraftment success without promoting excessive nonrelapse mortality in medically infirm patients requiring hematopoietic cell transplantation. In this paper, we studied this same lowtoxicity regimen as a means of promoting engraftment of unrelated donor hematopoietic cell transplantation in patients with Fanconi anemia (FA). All patients tolerated the regimen well with no mucositis or other severe toxicities. Of six patients transplanted, five achieved stable mixed or full donor chimerism. Acute and chronic GVHD occurred in four and three patients, respectively. Three patients are alive and well at a median of 45.9 (range, 20.9-68.1) months after transplant. In summary, this FLU-based regimen facilitates stable engraftment of unrelated PBSCs, but is associated with significant chronic GVHD.
Introduction
Fanconi anemia (FA) is a rare, heterogeneous disorder characterized by progressive marrow failure and susceptibility to malignancies. Hematopoietic cell transplantation (HCT), although the only known cure for the hematological manifestations of this disease, is associated with considerable toxicity in FA patients because of their underlying DNA repair defects and inability to tolerate conventional doses of cytotoxic therapy. 1 Studies incorporating reduced doses of chemotherapy have allowed high rates of engraftment and excellent survival with minimal toxicity when using HLA-matched sibling donors. 2 However, similar results have been more difficult to achieve when using HLA-matched unrelated donors because of higher rates of both graft rejection and GVHD. 3 A retrospective analysis of unrelated donor transplants conducted by the Center for International Blood and Marrow Transplant Research (CIBMTR) registry showed a benefit when using fludarabine (FLU)-rather than non-FLU-based regimens. 4 However, to promote engraftment in the unrelated donor setting, FLU historically has been combined with other agents, such as TBI at moderate doses, which has contributed to additional toxicity. 5 In particular, irradiation at doses exceeding 4-5 Gy has been associated with additional acute toxicity and secondary malignancies in FA patients, especially squamous cell carcinomas of the head and neck. 6, 7 There has also been some precedence in eliminating TBI altogether when using unrelated donors to reduce these late effects. 8 Accordingly, we reasoned that a well-established nonmyeloablative conditioning regimen, 9, 10 typically reserved for high-risk, medically fragile patients, which uses FLU and low-dose TBI in combination with cyclosporine and mycophenolate mofetil, could also be attempted in FA patients to facilitate engraftment without excessive toxicity. Even when used to salvage a high-risk, non-FA population that rejected previous allogeneic transplants, this regimen was able to promote sustained engraftment in 87% of patients, with four out of five patients who failed to engraft having myelofibrosis. 11 This study was also designed to reduce and possibly eliminate the already low-dose of TBI for future cohorts on the basis of high rates of engraftment. Finally, as we have shown that FA patients undergoing HLA-matched sibling transplants can tolerate a dose of cyclophosphamide (CY) 60 mg/kg for conditioning, we hypothesized that a regimen that incorporated no alkylating agents and only a low-dose of TBI in the HLA-matched, unrelated donor setting would also be similarly tolerable. Thus, the goal of this trial was to evaluate engraftment and toxicity associated with FLU and low-dose TBI in patients with FA.
Materials and methods

Patient characteristics
Between August 2001 and September 2006, six patients confirmed as having FA by chromosomal breakage analysis and requiring allogeneic transplantation for aplastic anemia, but having no HLA-matched sibling donors, were enrolled on FHCRC protocol 1444 at four different centers. Participating centers included the Fred Hutchinson Cancer Research Center, Seattle, WA, USA; the Children's Memorial Hospital, Chicago, IL, USA; the Monroe Carell Jr Children's Hospital at Vanderbilt, Nashville, TN, USA; and the Primary Children's Medical Center, Salt Lake City, UT, USA. All patients and/or legal guardians provided informed consent using institutional review board approved documents. Patients were between the ages of 9.9-12.1 (median, 10.6) years at the time of transplant. Additional patient characteristics are detailed in Table 1 .
Donor characteristics
Patients and donors were typed at HLA-A, -B, -C, -DRB1 and -DQB1 using high-resolution DNA-based methods. Donors were matched with the patient for HLA-DRB1 and -DQB1, and either matched (n ¼ 4) or mismatched for a single allele at HLA-A, -B or -C (n ¼ 2). PBSCs were mobilized with G-CSF at a dose of 10 mg/kg for 5 days. All donors provided informed consent as per National Marrow Donor Program guidelines. Additional donor characteristics can be found in Table 1 .
Transplant characteristics
The conditioning regimen consisted of FLU 30 mg/m 2 from days À4 to À2 and 2 Gy TBI on day 0. 9,10 PBSCs were T-cell replete and infused on day 0. Infused cell doses can be found in Table 1 . Postgrafting immunosuppression consisted of cyclosporine from days À3 to þ 100, then tapered to day þ 177, and mycophenolate mofetil from days 0 to þ 40, then tapered to day þ 96.
Outcome measures and statistical methods
Graft rejection was defined as o5%, mixed chimerism between 5 and 95% and full donor chimerism as 495% donor CD3 chimerism. CD3 chimerism was evaluated on days þ 28, þ 84 and þ 365 (or more frequently), either by fluorescent in situ hybridization for sex-mismatched transplants or by analysis of genomic DNA for variable number of tandem repeats for sex-matched transplants. GVHD was graded as per established methods. 12 Late-onset acute GVHD was defined as any acute GVHD occurring beyond day þ 100. An infectious episode was defined only if a pathogen was identified and treatment was prescribed. Because of the small sample size of this cohort, variables that may have affected outcomes were not incorporated into a multivariate analysis. Stopping rules for grade IV regimen-related toxicity before day þ 28 were not met. Protocol oversight was maintained by a dedicated data safety monitoring board, which met at least every 6 months. 
Results
Engraftment and hematopoietic recovery Engraftment was achieved in five out of six patients, of whom three developed mixed and two developed full donor chimerism. Median time to achieve an ANC of 500/mm 3 was day þ 16 (range, þ 13 to þ 17) and that for plts count 450 000/mm 3 without transfusion was day þ 15 (range, þ 14 to þ 18). All five patients had improvement from baseline hematological blood counts irrespective of the extent of donor chimerism. Graft failure occurred in one patient and was not rectified after a second PBSC transplant on day þ 34 from the same donor with no additional conditioning. However, engraftment was subsequently achieved when the patient was conditioned with FLU and antithymocyte globulin before receiving a third PBSC transplant from the same donor. He is currently alive and doing well with ameliorated blood counts and mixed donor chimerism (Figure 1 ). GVHD Four patients developed acute GVHD with stage II skin (n ¼ 3), stage III gut (n ¼ 1) and stage III liver (n ¼ 1), resulting in overall grades of acute GVHD of I (n ¼ 1), II (n ¼ 2) and III (n ¼ 1). In all cases, systemic steroids were given and the mycophenolate mofetil taper was held. No patient developed late-onset acute GVHD. Of the five evaluable patients, three developed refractory chronic GVHD at 83, 84 and 102 days after HCT that required prolonged treatment with systemic steroids, as well as tertiary immunosuppressive therapy.
Regimen-related toxicity
Infections
All three patients with chronic GVHD developed multiple episodes of late systemic infections. Patient 1 had 15 (bacterial, 10; viral, 4; fungal, 1) infections at a median of 293 (range, 23-690) days, patient 5 had 14 (bacterial, 12; viral, 2) infections at a median of 415 (range, 139-741) days and patient 6 had 12 (bacterial, 9; viral, 1; fungal, 2) infections at a median of 432 (range, 65-487) days after HCT. Patient 4 was treated for one bacterial infection before being taken off the study for graft rejection, whereas patients 2 and 3, neither of whom developed chronic GVHD, did not have any documented infections.
OS
With a median follow-up of 26 (16.3-68.1) months after HCT, three out of six patients are alive and well. As of last follow-up, all three remain transfusion independent and have not developed any secondary malignancies to date, and two have discontinued all immunosuppressive drugs.
Discussion
FA is characterized by an intrinsic sensitivity to DNAdamaging agents, and thereby presents a challenging therapeutic balance between providing enough conditioning to allow durable engraftment without promoting excessive acute toxicity. In this study, we evaluated the use of FLU in combination with TBI in the conditioning of FA patients before unrelated donor grafts. The regimen that included 2 Gy TBI was well tolerated and engraftment was attained in most cases. Similar to that reported for non-FA patients transplanted for malignant diseases, 11 these findings showed that low-intensity conditioning with FLU allowed for stable engraftment. However, chronic refractory GVHD remained a substantial problem in our population, and novel strategies to reduce GVHD will be required in future protocols. Several patients developed late infections complicating their clinical course. Because most infections were seen years after HCT and only in those patients having chronic GVHD, it is likely that functional defects of chronic GVHD itself, as well as effects of chronic immunosuppression, are the likely causes rather than acute regimen-related toxicity.
The major problem identified with this regimen was the high rate of chronic GVHD, which contributed to the deaths of three patients. The most likely etiology is the use of G-CSF-mobilized PBSC grafts, which are associated with higher rates of chronic GVHD compared with marrow grafts. 13, 14 Despite the presence of chronic GVHD and the immunological drive of donor cells to promote GVHD in two out of three patients with mixed chimerism, conversion to full donor chimerism was not observed. The etiology of this is unclear, but similar observations have been noted when transplanting other nonmalignant diseases treated with a conditioning regimen similar to ours. 15 It is noteworthy that the long-term significance of prolonged mixed chimerism is uncertain in FA. Theoretically, although the persistence of residual FA cells may not necessarily affect long-term engraftment, there is concern that these cells may transform into leukemia or myelodysplastic syndrome over time. However, when evaluating the results of a joint study between our group and Curitiba, Brazil, 2 of the 43 patients who underwent HLA-matched sibling transplantation and conditioning with CY 60 mg/ kg, over half developed mixed donor-host chimerism, and to date none have developed leukemia or MDS with a median follow-up of 6.7 (range 3.4-10.6) years (personal communication, R Pasquini and C Bonfim). As the followup of most patients in this study is still relatively early, such observations are interesting, but the benefit of mixed chimerism cannot be confirmed without the ongoing longitudinal follow-up. This is in contrast to that reported in the natural history of FA, in which, without transplant, one study indicated an actuarial risk as high as 67% by the age of 40 years. 16 Absolute neutrophil count Finally, development of chronic GVHD in our study could be attributed to the inadequacy of early postgrafting immunosuppression. Although prolonged immunosuppression with cyclosporine and mycophenolate mofetil helped to establish stable engraftment in our protocol, the prevention of GVHD will require a more aggressive elimination of actively proliferating alloreactive donor T-cell clones that emerge early after HCT. One approach worth considering would be the use of only marrow grafts to reduce the number of T cells, or adding other agents to target more specific in vivo T-cell depletion, such as either adding antithymocyte globulin during conditioning 17, 18 or, as shown in non-FA patients, adding a single dose of CY after HCT. 19 Another approach would be to deplete donor T cells ex vivo and infusing CD34selected stem cells. 20 It is thus clear from our results and from published studies that successor transplant trials for FA need to incorporate more efficient T-cell suppression/depletion strategies while attempting dose deescalation or elimination of TBI to decrease toxicity and late effects.
Other groups have published FLU-based regimens for unrelated donors using marrow and/or T-cell depletion methods with promising results. Wagner et al. 4 evaluated CIBMTR registry data showing the survival advantage of FLU-based regimens. Yabe et al. 17 reported on 27 FA patients receiving alternative donor transplants, of whom 24 received 5-6 out of 6 HLA unrelated donor marrows. Using a regimen containing 3-4.5 Gy thoracoabdominal irradiation or TBI, FLU, CY and ATG, engraftment was seen in 26 out of 27, acute GVHD grades II-III was observed in 3 out of 26 and chronic GVHD in 8 out of 26 patients, resulting in an OS of 96.3%. Chaudhury et al. 20 reported on alternative donor transplant patients, of whom 10 out of 18 received CD34 þ , T-cell-depleted PBSCs or marrow grafts from HLA-matched or -mismatched unrelated donors, preceded by 450 cGy TBI, FLU 150 mg/m 2 and CY 40 mg/kg. Outcomes for the entire group showed that all engrafted, one patient developed grades II-III GVHD, which progressed to chronic GVHD, and the 5-year disease-free survival was 66.6%. Some groups have also incorporated alemtuzumab, a MoAb against CD52, as a means of depleting T cells in vivo with promising results. 21, 22 In contrast, MacMillan et al. 5 reported on a TBI dose-escalation study in which 21 out of 29 patients received unrelated donor T-cell-depleted marrow grafts. Conditioning included CY 40 mg/kg, TBI 450 or 600 cGy, and ATG. Results showed that, for the entire cohort, engraftment was 63%, grades II-IV acute GVHD was 32%, chronic GVHD 0% and 1-year OS was low at 34%. Thus, ongoing prospective trials incorporating minimally toxic yet potently immunosuppressive strategies are necessary for successfully transplanting patients with FA.
We conclude that in patients with FA, our regimen with FLU and low-dose TBI was able to achieve stable engraftment with minimal early toxicity, but it was associated with unacceptably high rates of chronic GVHD for this patient population.
